Neues in der Prävention des Schlaganfalls

Hans-Christoph Diener; Matthias Endres; Christian Gerloff; Sven Poli

doi:10.1055/a-1719-9328

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie, Inhaltsverzeichnis

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie 2022; 09(02): 145-159
DOI: 10.1055/a-1719-9328

CME-Fortbildung

Neues in der Prävention des Schlaganfalls

Hans-Christoph Diener

,

Matthias Endres

,

Christian Gerloff

,

Sven Poli

Abstract

Diese Übersichtsarbeit referiert aktuelle Studien zur Prävention des Schlaganfalls und zur Funktionsverbesserung nach Schlaganfall. Die Autoren haben die wichtigsten Publikationen aus den Jahren 2020 und 2021 zusammengestellt.

Schlüsselwörter

Hirninfarkt - Gehirnblutung - transitorische ischämische Attacke - TIA - Geriatrie - ischämischer Insult - Sekundärprävention - intrazerebrale Blutung - Thrombozytenfunktionshemmer - Antikoagulation

Volltext

Referenzen

Literatur
1 Kitagawa K, Yamamoto Y, Arima H. et al. Effect of Standard vs Intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurology 2019; 76: 1309-1318
2 Boncoraglio GB, Del Giovane C, Tramacere I. Antihypertensive Drugs for secondary prevention after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2021; 52: 1974-1982
3 Hughes D, Judge C, Murphy R. et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA 2020; 323: 1934-1944
4 Milionis H, Ntaios G, Korompoki E. et al. Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. Int J Stroke 2020; 15: 377-384
5 Sabatine MS, Giugliano RP, Keech AC. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-1722
6 Schwartz GG, Steg PG, Szarek M. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097-2107
7 Amarenco P, Kim JS, Labreuche J. et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020; 382: 9
8 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
9 Cukierman-Yaffe T, Gerstein HC, Colhoun HM. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 2020; 19: 582-590
10 English C, MacDonald-Wicks L, Patterson A. et al. The role of diet in secondary stroke prevention. Lancet Neurol 2020;
11 Ntaios G, Papavasileiou V, Diener HC. et al. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017; 12: 589-596
12 Lip GYH, Keshishian A, Li X. et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018; 49: 2933-2944
13 Coleman CI, Peacock WF, Bunz TJ. et al. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke 2017;
14 Xian Y, Xu H, O'Brien EC. et al. Clinical Effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA Neurol 2019;
15 Kwok CS, Loke YK, Hale R. et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 2011; 76: 914-922
16 Ding M, Qiu C. Atrial Fibrillation, cognitive decline, and dementia: an epidemiologic review. Curr Epidemiol Rep 2018; 5: 252-261
17 Diener HC, Hart RG, Koudstaal PJ. et al. Atrial fibrillation and cognitive function: jacc review topic of the week. J Am Coll Cardiol 2019; 73: 612-619
18 Cadogan SL, Powell E, Wing K. et al. Anticoagulant prescribing for atrial fibrillation and risk of incident dementia. Heart 2021;
19 Lee S-R, Choi E-K, Park S-H. et al. Comparing warfarin and 4 direct oral anticoagulants for the risk of dementia in patients with atrial fibrillation. Stroke 2021; 52: 3459-3468
20 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339
21 Chiarito M, Sanz-Sánchez J, Cannata F. et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. The Lancet 2020; 395: 1487-1495
22 Wang Y, Wang Y, Zhao X. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11-19
23 Johnston SC, Easton JD, Farrant M. et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk tiA. NEJM 2018; 379: 215-225
24 Johnston SC, Amarenco P, Albers GW. et al. Ticagrelor versus Aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016; 375: 35-43
25 Johnston SC, Amarenco P, Denison H. et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020; 383: 207-217
26 Dawson J, Merwick Á, Webb A. et al. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. European Stroke Journal 2021; 6: CLXXXVII-CXCI
27 Adams Jr. HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24: 35-41
28 Hart RG, Diener HC, Coutts SB. et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429-438
29 Sacco RL, Prabhakaran S, Thompson JL. et al. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis 2006; 22: 4-12
30 Longstreth Jr WT, Kronmal RA, Thompson JL. et al. Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke 2013; 44: 714-719
31 Homma S, Sacco RL, Di Tullio MR. et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625-2631
32 Diener HC, Easton JD, Granger CB. et al. Design of randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT ESUS). Int J Stroke 2015; 10: 1309-1312
33 Diener HC, Sacco RL, Easton JD. et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380: 1906-1917
34 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. Eur Stroke J 2016; 1: 146-154
35 Hart RG, Connolly SJ, Mundl H. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. NEJM 2018; 379: 987
36 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the S . et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694
37 Healey JS, Gladstone DJ, Swaminathan B. et al. Recurrent Stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol 2019; 76: 764-773
38 Kasner SE, Swaminathan B, Lavados P. et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol 2018; 17: 1053-1060
39 Diener H-C, Chutinet A, Easton JD. et al. Dabigatran or aspirin after embolic stroke of undetermined source in patients with patent foramen ovale. Stroke 2021; 52: 1065-1068
40 Kasner SE, Lattanzi S, Fonseca AC. et al. Uncertainties and controversies in the management of ischemic stroke and transient ischemic attack patients with patent foramen ovale. Stroke 2021; 52: e806-e819
41 Elgendy AY, Saver JL, Amin Z. et al. Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale–associated stroke. JAMA Neurology 2020; 77: 878-886
42 Grau AJ, Weimar C, Buggle F. et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32: 2559-2566
43 Yiin GS, Howard DP, Paul NL. et al. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation 2014; 130: 1236-1244
44 Diener HC, Sacco RL, Easton JD. et al. Antithrombotic treatment of embolic stroke of undetermined source: RE-SPECT ESUS Elderly and renally impaired subgroups. Stroke 2020; 51: 1758-1765
45 Ntaios G, Swaminathan B, Berkowitz SD. et al. Efficacy and Safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis. Stroke 2019; 50: 2477-2485
46 Bayer-Karpinska A, Schwarz F, Wollenweber FA. et al. The carotid plaque imaging in acute stroke (CAPIAS) study: protocol and initial baseline data. BMC neurology 2013; 13: 201
47 Scheitz JF, Pare G, Pearce LA. et al. High-sensitivity cardiac troponin t for risk stratification in patients with embolic stroke of undetermined source. Stroke 2020; 51: 2386-2394
48 Geisler T, Poli S, Meisner C. et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke 2017; 12: 985-990
49 Kamel H, Longstreth Jr WT, Tirschwell DL. et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke 2019; 14: 207-214
50 Scacciatella P, Jorfida M, Biava LM. et al. Insertable cardiac monitor detection of silent atrial fibrillation in candidates for percutaneous patent foramen ovale closure. Journal of cardiovascular medicine 2019; 20: 290-296
51 Riordan M, Opaskar A, Yoruk A. et al. Predictors of atrial fibrillation during long-term implantable cardiac monitoring following cryptogenic stroke. J Am Heart Assoc 2020; 9: e016040
52 Víctor CU, Carolina PE, Jorge TR. et al. Incidence and predictive factors of hidden atrial fibrillation detected by implantable loop recorder after an embolic stroke of undetermined source. J Atr Fibrillation 2018; 11: 2078
53 Ziegler PD, Rogers JD, Ferreira SW. et al. Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. International journal of cardiology 2017; 244: 175-179
54 Cotter PE, Martin PJ, Ring L. et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology 2013; 80: 1546-1550
55 Christensen LM, Krieger DW, Hojberg S. et al. Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study. Eur J Neurol 2014; 21: 884-889
56 Kitsiou A, Rogalewski A, Kalyani M. et al. Atrial Fibrillation in patients with embolic stroke of undetermined source during 3 years of prolonged monitoring with an implantable loop recorder. Thrombosis Haemostasis 2021; 121: 826-833
57 Sanna T, Diener HC, Passman RS. et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 2478-2486
58 Bernstein RA, Kamel H, Granger CB. et al. Effect of Long-term continuous cardiac monitoring vs usual care on detection of atrial fibrillation in patients with stroke attributed to large- or small-vessel disease: the STROKE-AF randomized clinical trial. JAMA 2021; 325: 2169-2177
59 Buck BH, Hill MD, Quinn FR. et al. Effect of Implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the PER DIEM randomized clinical trial. JAMA 2021; 325: 2160-2168
60 Bonati LH, Kakkos S, Berkefeld J. et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. European Stroke Journal 2021; 6: 1-47
61 Halliday A, Bulbulia R, Bonati LH. et al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. The Lancet 2021;